Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.87

-2.6%

9:58 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: russwinter who wrote (5412)	1/12/2002 6:30:05 PM
From: Miljenko Zuanic	of 52153

After Roche lost interest for Celpene for HCV I lost interest for MAXM. IMO, Celpene will have limited utility in cancer (only as adjuvant). Regards the CEGE, I do not follow them well, but for the record I think that they have chance. However, business model focused on cancer therapy may become too risky. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next